Skip to main content

Table 1 Definitions of moderate and severe exacerbations used in the MT-04 trial

From: The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data

Criteria defining moderate exacerbations [24] Criteria defining severe exacerbations [13]
1 or more of the following criteria and must also result in a temporary change in treatment:
Nocturnal awakening(s) due to asthma requiring SABA use for at least 2 consecutive nights or an increase of at least 0.75 points in daily symptom score from baseline value on at least 2 consecutive days;
An increase from baseline in SABA use on at least 2 consecutive days (a minimum increase of 4 puffs per day);
A 20% or more decrease in peak expiratory flow from baseline on at least 2 consecutive mornings or evenings or a 20% or more decrease in FEV1 from baseline;
A visit to the emergency department or an unscheduled visit to the trial site for asthma treatment not requiring systemic corticosteroids.
1 or more of the following criteria:
A requirement for systemic corticosteroids for the treatment of asthma symptoms for at least 3 days;
An emergency department visit due to asthma requiring systemic corticosteroids, or a hospitalization for more than 12 h due to asthma.
  1. FEV1 Forced Expiratory Volume in 1 s, SABA Short-acting β2-agonists